Risk for symptomatic embolism can be predicted via echocardiographic vegetation features in patients with infective endocarditis.

Instylla, Inc. announced that it recently submitted the final module of its premarket approval (PMA) application to the FDA ...

The "liquid embolic agent" used as the glue in this embolization technique is called Onyx and is made by Medtronic, which funded the new trial. The embolization is minimally invasive: Doctors ...

NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the esteemed Journal of Vascular and ...

In this final PMA module, Instylla has submitted clinical study resultsto the FDA, advancing our pursuit of the indication ...

Embolic problems result in a greater degree of ischemia than thrombosis, as the embolus characteristically lodges in a "virgin" vascular bed with no prior collateral development. On the contrary ...

Instylla, Inc. is a privately held company based in Bedford, MA, focused on developing novel resorbable embolic agents to advance interventional radiology, with initial clinical applications in ...